Fermenta Biotech Ltd
Fermenta Biotech Q4 FY24 earnings call: Revenue & Margins
Q4 FY24 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹97Cr
- Net profit
- −₹7Cr
- Margin
- 5.53%
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Fermenta Biotech Ltd's Q4 FY24 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q4-FY24 Consolidated Operational Revenue: INR 973 Mn, down 7.5% YoY (Page 11) - Q4-FY24 Standalone Operational Revenue: INR 897 Mn, down 10.8% YoY (Page 9) - Volume of Vitamin D3 for Human Nutriti Quarterly EBITDA (Consolidated, Q4-FY24): INR 54 Mn, down 72.0% YoY (Q4-FY23: INR 193 Mn) - Quarterly Operating Margin (Consolidated, Q4-FY24): 5.55%, down from 18.35% YoY - Quarterly Prof
From Fermenta Biotech Ltd's Q4 FY24 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q4-FY24 Consolidated Operational Revenue: INR 973 Mn, down 7.5% YoY (Page 11)
- Q4-FY24 Standalone Operational Revenue: INR 897 Mn, down 10.8% YoY (Page 9)
- Volume of Vitamin D3 for Human Nutrition in Q4-FY24: 111% higher compared to Q3-FY24 but 18% lower in FY24 vs FY23 (Page 7)
- Average prices of Vitamin D3 for Human Nutrition in FY24: 5% higher compared to FY23 (Page 7)
2 more points from Fermenta Biotech Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Fermenta Biotech Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Fermenta Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Fermenta Biotech Ltd said on order book & pipeline — free account, 30 seconds.
Fermenta Biotech Ltd — Quarterly revenue & net profit
Fermenta Biotech Ltd Q4 FY24 results — key figures
| ₹ Cr | Q4 FY24 | Q3 FY24 | QoQ |
|---|---|---|---|
| Revenue | 97 | 99 | -1.6% |
| Operating profit (EBITDA) | 5 | 25 | -78.6% |
| Operating margin | 5.53% | 25.39% | -19.9 pp |
| Profit before tax | 1 | 16 | -94.3% |
| Net profit (PAT) | -7 | 10 | -171.5% |
| EPS (₹) | -2.36 | 3.35 | -170.4% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹133 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Fermenta Biotech's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmo (Q4 FY24)
1,759 Cr, a 5% YoY increase from Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY24 earnings call — and how it ranks against sector peers.
- Bharat Parenterals (Q4 FY24)
For Q4 FY 2024, consolidated revenue from operations was INR 67.82 crore, up 13.4% YoY (Q4 FY 2023: INR 59.82 crore). Key concall takeaways from Bharat…
- Themis Medicare (Q4 FY24)
97.82 Cr, up 22.11% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY24 earnings call — and how it ranks against sector peers.
- Amrutanjan Healt (Q4 FY24)
OTC: ₹108.37 Cr, up 27.57% YoY (Q4 FY23: ₹84.95 Cr) . Key concall takeaways from Amrutanjan Health Care Ltd's Q4 FY24 earnings call — and how it ranks against…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Fermenta Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Fermenta Biotech Ltd Q4 FY24 results?
Q4-FY24 Consolidated Operational Revenue: INR 973 Mn, down 7.5% YoY (Page 11) - Q4-FY24 Standalone Operational Revenue: INR 897 Mn, down 10.8% YoY (Page 9) - Volume of Vitamin D3 for Human Nutriti Quarterly EBITDA (Consolidated, Q4-FY24): INR 54 Mn, down 72.0% YoY (Q4-FY23: INR 193 Mn) - Quarterly Operating Margin (Consolidated, Q4-FY24): 5.55%, down from 18.35% YoY - Quarterly Prof
What is Fermenta Biotech Ltd share price analysis?
Fermenta Biotech Ltd currently shows a neutral. The stock trades at a P/E of 25.5 with a market cap of ₹1,395 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Fermenta Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.